Agnes Solon, MD
Rheumatology · Alexandria, LANPI 1558362004
Payments from drug & device makers
Across 601 payments — averaging $204.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$117K
- AbbVie$1K
- UCB, Inc.$717
- Pfizer$578
- Johnson & Johnson$532
- Lilly USA, LLC$504
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$98,85081%
- Travel & lodging$13,19011%
- Food & beverage$10,4859%
- Education$2050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 223 | $116,526 |
| AbbVie | 73 | $1,301 |
| UCB, Inc. | 49 | $717 |
| Pfizer | 41 | $578 |
| Johnson & Johnson | 22 | $532 |
| Lilly USA, LLC | 28 | $504 |
| Novartis | 23 | $443 |
| ANI Pharmaceuticals, Inc. | 21 | $403 |
| GSK | 18 | $281 |
| Genentech USA, Inc. | 10 | $163 |
| Sanofi | 9 | $157 |
| Regeneron Healthcare Solutions, Inc. | 13 | $154 |
| Medexus Pharma, Inc. | 20 | $120 |
| Radius Health, Inc. | 5 | $112 |
| E.r. Squibb & Sons, L.L.C. | 8 | $112 |
| AstraZeneca(2 entities) | 5 | $93 |
| Aurinia Pharma U.S., Inc. | 6 | $84 |
| Bristol Myers Squibb | 4 | $54 |
| Mallinckrodt Hospital Products Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Sandoz | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Zyla Life Sciences, Inc. | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Theratechnologies Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,730 in reported general payments places this provider in the 80th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 153 | $1,182,634 |
| RinvoqUpadacitinib | 108 | $762,622 |
| XeljanzTofacitinib Citrate | 87 | $503,628 |
| Humira(Cf) PenAdalimumab | 52 | $479,507 |
| Humira PenAdalimumab | 51 | $354,727 |
| Xeljanz XrTofacitinib Citrate | 42 | $241,430 |
| EnbrelEtanercept | 28 | $181,781 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 25 | $160,568 |
| ActemraTocilizumab | 34 | $156,899 |
| BenlystaBelimumab | 26 | $95,077 |
| KevzaraSarilumab | 20 | $86,630 |
| SimponiGolimumab | 12 | $79,173 |
| ProliaDenosumab | 45 | $77,125 |
| Humira(Cf)Adalimumab | 11 | $71,957 |
| Actemra ActpenTocilizumab | 14 | $64,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,301 | $834,579119 claims |
| PfizerXeljanz | $578 | $503,62887 claims |
| AmgenEnbrel, Prolia | $116,526 | $258,90673 claims |
| GSKBenlysta | $281 | $95,07726 claims |
| SanofiKevzara | $157 | $86,63020 claims |
| Johnson & JohnsonSimponi | $532 | $79,17312 claims |
| Radius Health, Inc.Tymlos | $112 | $60,83221 claims |
| Medexus Pharma, Inc.Rasuvo | $120 | $10,20019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Alexandria
- Miguel Garcia-CaroAlexandria$14K
- Stephen LindseyBaton Rouge$3.6M
- Enrique MendezLake Charles$1.9M
- Aaron BroadwellShreveport$1.7M
- Saravanan ThiagarajanBaton Rouge$1.2M
- Jyothi MallepalliMonroe$998K
- Lesley SaketkooNew Orleans$294K
- William DavisNew Orleans$288K
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.